Browse Studies — Arctuva

Phase 1

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Estimated

~$150 – $4,200

Actual pay is set by the research site.

PeproMene Bio, Inc.NCT05370430

Phase 1

A Pilot / Feasibility Study of Autologous CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine in Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma

This phase I trial studies the safety and feasibility of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T cells in combination with the CM…

High Grade B-Cell Non-Hodgkin's LymphomaIntermediate Grade B-Cell Non-Hodgkin's LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

City of Hope Medical CenterNCT05801913

Phase 1

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unme…

B-Cell Non-Hodgkin's Lymphoma (NHL)Lymphoma, Non-HodgkinsLymphomas Non-Hodgkin's B-Cell+12 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.